China Resources Pharmaceutical (3320) and Jiangzhong Pharmaceutical released financial details for the nine months ended 30 September 2025. Jiangzhong Pharmaceutical’s revenue reached RMB2,933,172,225.19, and net profit stood at RMB742,687,211.39 for the period. The net increase in cash and cash equivalents was RMB115,014,135.29, while the balance of cash and cash equivalents at the end of the period was RMB766,938,443.98.

As of 30 September 2025, Jiangzhong Pharmaceutical reported total assets of RMB6,891,491,627.19, total liabilities of RMB2,444,005,425.11, and owner’s equity of RMB4,447,486,202.08. These figures, prepared in accordance with PRC Generally Accepted Accounting Principles, have not been reviewed or audited and may require adjustments.

China Resources Pharmaceutical controls an effective interest of approximately 26.12% in Jiangzhong Pharmaceutical through a non-wholly owned subsidiary, recognizing Jiangzhong Pharmaceutical as a subsidiary of the Group. The quarterly report issued by Jiangzhong Pharmaceutical does not represent the entire operational or financial status of China Resources Pharmaceutical, and caution is advised when interpreting these figures.